Literature DB >> 10811631

Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells.

U M Malyankar1, M Scatena, K L Suchland, T J Yun, E A Clark, C M Giachelli.   

Abstract

Osteopontin protects endothelial cells from apoptosis induced by growth factor withdrawal. This interaction is mediated by the alpha(v)beta(3) integrin and is NF-kappaB-dependent (Scatena, M., Almeida, M., Chaisson, M. L., Fausto, N., Nicosia, R. F., and Giachelli, C. M. (1998) J. Cell Biol. 141, 1083-1093). In the present study we used differential cloning to identify osteopontin-induced, NF-kappaB-dependent genes in endothelial cells. One of the genes identified in this screen was osteoprotegerin, a member of the tumor necrosis factor receptor superfamily. By Northern and Western blot analysis, osteoprotegerin mRNA and protein levels were very low in endothelial cells plated on the non-integrin cell attachment factor, poly-d-lysine. In contrast, osteoprotegerin mRNA and protein levels were induced 5-7-fold following alpha(v)beta(3) ligation by osteopontin. Osteoprotegerin induction by osteopontin was time-dependent and observed as early as 3 h following treatment. NF-kappaB inactivation achieved by over expression of an IkappaB super repressor in endothelial cells completely inhibited osteoprotegerin induction by osteopontin. Finally, purified osteoprotegerin protected endothelial cells with inactive NF-kappaB from apoptosis induced by growth factor deprivation. These data suggest that alpha(v)beta(3)-mediated endothelial survival depends on osteoprotegerin induction by NF-kappaB and indicate a new function for osteoprotegerin in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811631     DOI: 10.1074/jbc.C000290200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

Review 1.  The role of alpha(v)beta(3) in prostate cancer progression.

Authors:  Carlton R Cooper; Christopher H Chay; Kenneth J Pienta
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

2.  Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.

Authors:  Amit Noheria; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2010-03-25       Impact factor: 2.689

3.  Evaluation of Serum Fetuin-A and Osteoprotegerin Levels in Patients with Psoriasis.

Authors:  Mehmet Genc; Murat Can; Berrak Guven; Saniye Cinar; Cagatay Buyukuysal; Bilgehan Acikgoz; Ayca Gorkem Mungan; Serefden Acikgoz
Journal:  Indian J Clin Biochem       Date:  2016-05-06

4.  Bilateral cavernous internal carotid aneurysms in a child with juvenile paget disease and osteoprotegerin deficiency.

Authors:  C A Allen; B L Hart; C L Taylor; C L Clericuzio
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-18       Impact factor: 3.825

5.  Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.

Authors:  Ajjai Alva; Susan Slovin; Stephanie Daignault; Michael Carducci; Robert Dipaola; Ken Pienta; David Agus; Kathleen Cooney; Alice Chen; David C Smith; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-11-04       Impact factor: 3.850

6.  Biomarkers associated with pulse pressure in African-Americans and non-Hispanic whites.

Authors:  Thais Coutinho; Stephen T Turner; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2011-10-20       Impact factor: 2.689

7.  Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing.

Authors:  Alessandra Colombini; Giovanni Lombardi; Emanuela Galliera; Giada Dogliotti; Pietro Randelli; Alexander Meerssemann; Giuseppe Mineo; Paolo Cabitza; Massimiliano Marco Corsi
Journal:  Int Orthop       Date:  2010-07-11       Impact factor: 3.075

8.  Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality.

Authors:  Wolfgang Lieb; Philimon Gona; Martin G Larson; Joseph M Massaro; Izabella Lipinska; John F Keaney; Jian Rong; Diane Corey; Udo Hoffmann; Caroline S Fox; Ramachandran S Vasan; Emelia J Benjamin; Christopher J O'Donnell; Sekar Kathiresan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

9.  Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis.

Authors:  J H Kang; H M Ko; J S Moon; H I Yoo; J Y Jung; M S Kim; J T Koh; W J Kim; S H Kim
Journal:  J Dent Res       Date:  2014-09-25       Impact factor: 6.116

10.  Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact.

Authors:  Penny E Reid; Nicola J Brown; Ingunn Holen
Journal:  Mol Cancer       Date:  2009-07-15       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.